Vectorite Biomedical, Inc.(TW:4170)
NT$11.00+0.05 (+0.00%)
TW:4170
Vectorite Biomedical, Inc. financials statements
NT$11.00
At close:+0.05 (+0.00%)
Vectorite Biomedical, Inc. (4170) Ratios
Vectorite Biomedical, Inc. Ratios
TW:4170's free cash flow for Q2 2026 was NT$-4.88M. For the 2026 fiscal year, TW:4170's free cash flow was decreased by NT$-83.00K and operating cash flow was NT$-4.80M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 11.85 | 14.06 | 17.53 | 14.93 | 15.07 |
| Quick Ratio | 10.93 | 13.06 | 16.74 | 14.61 | 14.64 |
| Cash Ratio | 1.59 | 2.06 | 1.99 | 1.79 | 2.36 |
| Solvency Ratio | 4.26 | -1.35 | 0.12 | -0.72 | 0.97 |
| Operating Cash Flow Ratio | -0.36 | -0.78 | 0.10 | 0.95 | -3.96 |
| Short-Term Operating Cash Flow Coverage | -32.87 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 167.41M | NT$ 185.27M | NT$ 201.88M | NT$ 207.57M | NT$ 224.61M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.06 | 1.05 | 1.06 | 1.06 |
| Debt Service Coverage Ratio | -73.63 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -1991.64 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 1.84 | 1.78 | 3.63 | 1.29 | 1.51 |
| Profitability Margins | |||||
| Gross Profit Margin | 35.31% | 29.37% | 29.40% | 1.65% | -8.60% |
| EBIT Margin | -35.68% | -44.96% | -28.88% | -71.16% | -147.40% |
| EBITDA Margin | -22.42% | -29.79% | -12.48% | -50.51% | -90.15% |
| Operating Profit Margin | -35.68% | -44.96% | -28.88% | 71.16% | -147.34% |
| Pretax Profit Margin | 156.57% | -69.37% | -11.87% | -61.64% | 28.95% |
| Net Profit Margin | 156.57% | -69.33% | -11.82% | -61.55% | 29.05% |
| Continuous Operations Profit Margin | 156.57% | -69.37% | -11.87% | -61.64% | 28.95% |
| Net Income Per EBT | 100.00% | 99.95% | 99.59% | 99.85% | 100.35% |
| EBT Per EBIT | -438.84% | 154.29% | 41.09% | -86.63% | -19.65% |
| Return on Assets (ROA) | 18.87% | -9.70% | -1.46% | -5.67% | 1.70% |
| Return on Equity (ROE) | 19.83% | -10.29% | -1.53% | -5.99% | 1.79% |
| Return on Capital Employed (ROCE) | -4.44% | -6.53% | -3.67% | 6.78% | -8.90% |
| Return on Invested Capital (ROIC) | -4.44% | -6.53% | -3.67% | 6.77% | -8.90% |
| Return on Tangible Assets | 18.88% | -9.85% | -1.53% | -5.96% | 1.78% |
| Earnings Yield | 15.71% | -6.32% | -0.78% | -5.22% | 1.99% |
| Efficiency Ratios | |||||
| Receivables Turnover | 19.23 | 8.81 | 9.81 | 7.46 | 15.43 |
| Payables Turnover | 43.18 | 35.70 | 32.75 | 13.26 | 11.51 |
| Inventory Turnover | 2.65 | 2.76 | 3.93 | 8.74 | 4.31 |
| Fixed Asset Turnover | 0.36 | 0.34 | 0.31 | 0.23 | 0.15 |
| Asset Turnover | 0.12 | 0.14 | 0.12 | 0.09 | 0.06 |
| Working Capital Turnover Ratio | 0.33 | 0.29 | 0.26 | 0.19 | 0.18 |
| Cash Conversion Cycle | 148.09 | 163.51 | 118.95 | 63.16 | 76.53 |
| Days of Sales Outstanding | 18.98 | 41.45 | 37.20 | 48.92 | 23.66 |
| Days of Inventory Outstanding | 137.56 | 132.28 | 92.89 | 41.77 | 84.59 |
| Days of Payables Outstanding | 8.45 | 10.22 | 11.15 | 27.54 | 31.72 |
| Operating Cycle | 156.54 | 173.73 | 130.10 | 90.69 | 108.25 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.13 | -0.26 | 0.03 | 0.34 | -1.81 |
| Free Cash Flow Per Share | -0.22 | -0.33 | -0.08 | 0.32 | -1.85 |
| Dividend Paid and CapEx Coverage Ratio | -1.45 | -4.05 | 0.27 | 16.56 | -36.65 |
| Capital Expenditure Coverage Ratio | -1.45 | -4.05 | 0.27 | 16.56 | -36.65 |
| Operating Cash Flow Coverage Ratio | -15.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | -0.09 | -0.20 | 0.02 | 0.34 | -2.29 |
| Free Cash Flow Yield | -1.60% | -2.26% | -0.41% | 2.73% | -16.05% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 6.36 | -15.76 | -129.33 | -19.25 | 50.22 |
| Price-to-Sales (P/S) Ratio | 9.96 | 10.97 | 15.20 | 11.78 | 14.63 |
| Price-to-Book (P/B) Ratio | 1.26 | 1.63 | 1.97 | 1.15 | 0.90 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -62.54 | -44.16 | -245.63 | 36.60 | -6.23 |
| Price-to-Operating Cash Flow Ratio | -105.76 | -55.07 | 654.20 | 34.39 | -6.40 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | -0.03 | 1.72 | 0.05 | -0.46 |
| Enterprise Value Multiple | -42.59 | -35.05 | -118.16 | -22.04 | -14.72 |
| Enterprise Value | 586.49M | 603.21M | 823.84M | 477.68M | 381.80M |
| EV to EBITDA | -42.59 | -35.05 | -118.16 | -22.04 | -14.72 |
| EV to Sales | 9.55 | 10.44 | 14.75 | 11.13 | 13.27 |
| EV to Free Cash Flow | -59.96 | -42.03 | -238.31 | 34.58 | -5.65 |
| EV to Operating Cash Flow | -101.38 | -52.41 | 634.70 | 32.49 | -5.80 |
| Tangible Book Value Per Share | 11.09 | 8.77 | 9.35 | 9.57 | 12.19 |
| Shareholders’ Equity Per Share | 11.09 | 8.90 | 9.83 | 10.07 | 12.80 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Revenue Per Share | 1.41 | 1.32 | 1.28 | 0.98 | 0.79 |
| Net Income Per Share | 2.20 | -0.92 | -0.15 | -0.60 | 0.23 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | -4.39 | 1.54 | 0.41 | 0.87 | -0.20 |
| Research & Development to Revenue | 0.25 | 0.29 | 0.12 | 0.13 | 0.46 |
| SG&A to Revenue | 0.46 | 0.45 | 0.46 | 0.60 | 0.93 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.06 | 0.29 | -0.20 | -0.56 | -7.90 |
Currency in TWD
